Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹1,478 Cr
Revenue (TTM)
₹462 Cr
Net Profit (TTM)
₹57 Cr
ROE
16.4 %
ROCE
18.4 %
P/E Ratio
26.1
P/B Ratio
4.8
Industry P/E
26.59
EV/EBITDA
14.4
Div. Yield
0 %
Debt to Equity
0.4
Book Value
₹294.2
EPS
₹55.1
Face value
10
Shares outstanding
10,376,198
CFO
₹245.01 Cr
EBITDA
₹463.40 Cr
Net Profit
₹242.27 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Kwality Pharma
| 28.5 | -8.5 | 26.4 | 66.7 | 66.7 | 91.0 | -- |
|
BSE Healthcare
| -4.7 | -5.8 | -5.4 | 1.3 | 23.7 | 14.0 | 10.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Kwality Pharma
| 27.8 | 113.5 | 5.3 | -58.5 | 1,536.1 | 114.1 | -54.4 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Kwality Pharma
|
1,424.1 | 1,477.6 | 461.7 | 56.5 | 18.6 | 20.6 | 26.1 | 4.8 |
| 2,791.2 | 34,920.1 | 5,201.6 | 1,014.6 | 22.9 | 25 | 34.4 | 7.6 | |
| 7,827.5 | 19,544.3 | 2,177.5 | 200.9 | 11.3 | 26.5 | 97.3 | 23.5 | |
| 1,565.8 | 11,917.5 | 2,089.5 | 622.0 | 31.3 | 20.4 | 19.4 | 3.6 | |
| 1,332.1 | 18,429.0 | 3,078.2 | 469.4 | 26.4 | 14.9 | 42.7 | 5.1 | |
| 1,961.1 | 31,410.1 | 4,193.0 | 753.8 | 22.7 | 20.8 | 41.7 | 7.8 | |
| 4,887.1 | 22,333.8 | 2,482.3 | 853.6 | 33.7 | 18.9 | 26.2 | 5.6 | |
| 4,778.6 | 7,918.9 | 1,348.5 | 293.5 | 28.1 | 50.7 | 27 | 11.4 | |
| 388.9 | 7,603.2 | 1,432.0 | 149.0 | 19.1 | 7.9 | 50.7 | 3.1 | |
| 971.2 | 8,938.5 | 4,725.6 | 528.7 | 14.9 | 20.7 | 17.5 | 3.0 |
No Review & Analysis are available.
Manufacture of pharmaceuticals, medicinal chemical and botanical products
Incorporated
1983
Chairman
--
Managing Director
Ramesh Kumar
Headquarters
Amritsar, Punjab
Website
Looking for more details about Kwality Pharmaceuticals Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
The share price of Kwality Pharmaceuticals Ltd is ₹1,424.05 (BSE) as of 02-Apr-2026 IST. Kwality Pharmaceuticals Ltd has given a return of 66.67% in the last 3 years.
The P/E ratio of Kwality Pharmaceuticals Ltd is 26.13 times as on 02-Apr-2026, a 2 discount to its peers’ median range of 26.59 times.
The P/B ratio of Kwality Pharmaceuticals Ltd is 4.84 times as on 02-Apr-2026, a 8 premium to its peers’ median range of 4.49 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
22.63
|
3.43
|
|
2024
|
17.85
|
1.90
|
|
2023
|
16.47
|
1.60
|
|
2022
|
5.02
|
3.34
|
|
2021
|
3.84
|
0.96
|
The 52-week high and low of Kwality Pharmaceuticals Ltd are Rs 1,740.00 and Rs 666.00 as of 04-Apr-2026.
Kwality Pharmaceuticals Ltd has a market capitalisation of ₹ 1,478 Cr as on 02-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Kwality Pharmaceuticals Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹19.95
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.